CA-VERIMATRIX
3.9.2024 17:46:29 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX, FR0010291245), a global leader in powering the modern connected world with people-centered security, today announced its exciting plans for IBC 2024 taking place from September 13-17 in Amsterdam. Verimatrix’s IBC booth 1.C65 is set to become "Broadcast Beach," a vibrant, surf and sand-themed experience designed to transport attendees to the sunny shores of San Diego (home of Verimatrix’s U.S. office), while showcasing the company’s robust suite of security solutions, including its latest anti-piracy solution, Counterspy.
Counterspy, a new product in the Verimatrix Streamkeeper family, is a groundbreaking solution designed to tackle the escalating threat of digital video piracy in bold new ways. It offers unparalleled protection with a focus on tangible revenue-saving benefits for customers. IBC attendees will be able to experience a live demonstation that showcases how Counterspy customers can:
- Reduce Video Piracy: Counterspy provides a formidable defense against unauthorized access, significantly cutting down on piracy incidents and securing content across platforms.
- Protect Media Apps: With its advanced app protection and telemetry features, Counterspy shields media apps from reverse engineering, man-in-the-middle attacks, and other malicious activities, ensuring that only legitimate users can access content – and providing customers with a way to monitor and respond to piracy threats in real-time.
- Unlock Access to More Premium Content: By safeguarding content with Counterspy, operators can confidently expand their premium content offerings, meeting studio security requirements.
- Reduce CDN Costs: Counterspy directly addresses the issue of CDN leeching, enabling operators to cut CDN costs dramatically (one Verimatrix customer saw their CDN expenses drop by 50% after implementing Counterspy)
- Boost Paid Subscribers: By enhancing content security and reducing piracy, Counterspy helps customers maintain a trustworthy service vs. pirate services, which in turn helps drive subscriber growth and revenue.
The Verimatrix Broadcast Beach-themed booth at IBC 2024 will feature:
- Surfside Check-In: The first stop in the serene beachfront oasis where attendees can check in with a host and grab some wave-breaking Verimatrix swag.
- Counterspy Cove: Grab a seat at one of the high-back deck tables and interact with a live demo for Verimatrix Counterspy, the ultimate in video security defense, seamlessly shielding media apps from piracy, preventing CDN leeching, reducing credential theft, and ensuring substantial revenue protection.
- Revenue Protection Cabanas: Reserve a cabana equipped with hammocks and interactive displays to comfortably engage with and learn about award-winning Verimatrix Streamkeeper solutions.
- Cyber Surf Shack: Dive into a surf-themed espresso bar adorned with surfboards and beach cruisers, symbolizing Verimatrix’s agility and adaptability.
Attendees are invited to kick off their shoes and soak up some fun in the sun while staff from Verimatrix highlight the latest in secure streaming, bulletproof cybersecurity, and layered anti-piracy measures. To book at meeting with a Verimatrix security specialist during IBC 2024, email dvanmeter@verimatrix.com or alternatively, book a meeting online.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903597006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom